PE20190321A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
PE20190321A1
PE20190321A1 PE2018003289A PE2018003289A PE20190321A1 PE 20190321 A1 PE20190321 A1 PE 20190321A1 PE 2018003289 A PE2018003289 A PE 2018003289A PE 2018003289 A PE2018003289 A PE 2018003289A PE 20190321 A1 PE20190321 A1 PE 20190321A1
Authority
PE
Peru
Prior art keywords
hydroxyl
pharmaceutically acceptable
oleic acid
pharmaceutical compositions
cellulose
Prior art date
Application number
PE2018003289A
Other languages
English (en)
Inventor
Corswant Christian Von
Romain Bordes
Jonasson Simon Peter Michael Hjelm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20190321A1 publication Critical patent/PE20190321A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE i) UN PRINCIPIO ACTIVO COMO EL ACEITE DE SOYA O ACIDO OLEICO QUE EXISTE COMO UN ACEITE DISPERSADO EN UNA MATRIZ SOLIDA DE NANOCRISTALES DE CELULOSA, UN DERIVADO DE CELULOSA TAL COMO HIDROXIPROPILMETILCELULOSA, HIDROXIETILCELULOSA, ENTRE OTROS, Y OPCIONALMENTE UNA SAL FARMACEUTICAMENTE ACEPTABLE DE UN CATION METALICO POLIVALENTE TAL COMO CLORURO DE CALCIO; Y ii) UNO O MAS EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES TALES COMO MANITOL Y CELULOSA MICROCRISTALINA EN UNA PROPORCION DE 2:1. DICHA COMPOSICION SE PRESENTE EN FORMA DE COMPRIMIDO
PE2018003289A 2016-07-08 2017-07-06 Composiciones farmaceuticas PE20190321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PE20190321A1 true PE20190321A1 (es) 2019-03-04

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003289A PE20190321A1 (es) 2016-07-08 2017-07-06 Composiciones farmaceuticas

Country Status (20)

Country Link
US (1) US20200254046A1 (es)
EP (1) EP3481377A1 (es)
JP (1) JP2019520393A (es)
KR (1) KR20190026816A (es)
CN (1) CN109414409A (es)
AU (1) AU2017298873B2 (es)
BR (1) BR112019000240A2 (es)
CA (1) CA3029331A1 (es)
CL (1) CL2019000042A1 (es)
CO (1) CO2019000083A2 (es)
CR (1) CR20190007A (es)
DO (1) DOP2019000002A (es)
EA (1) EA201990162A1 (es)
GB (1) GB201611920D0 (es)
IL (1) IL263999A (es)
MX (1) MX2019000255A (es)
PE (1) PE20190321A1 (es)
PH (1) PH12019500024A1 (es)
SG (1) SG11201811223YA (es)
WO (1) WO2018015175A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022071461A1 (es) * 2020-10-02 2022-04-07
JPWO2022071463A1 (es) * 2020-10-02 2022-04-07

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238240A1 (en) * 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate
NZ595204A (en) * 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN102512664B (zh) * 2010-12-31 2015-04-01 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物
RU2664429C2 (ru) 2012-01-06 2018-08-17 Омтера Фармасьютикалс, Инк. Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA

Also Published As

Publication number Publication date
EA201990162A1 (ru) 2019-06-28
JP2019520393A (ja) 2019-07-18
WO2018015175A9 (en) 2018-03-29
SG11201811223YA (en) 2019-01-30
AU2017298873A1 (en) 2019-02-14
DOP2019000002A (es) 2019-03-31
WO2018015175A1 (en) 2018-01-25
IL263999A (en) 2019-01-31
MX2019000255A (es) 2019-05-27
PH12019500024A1 (en) 2019-11-04
AU2017298873B2 (en) 2020-04-30
CA3029331A1 (en) 2018-01-25
CN109414409A (zh) 2019-03-01
CR20190007A (es) 2019-03-05
CO2019000083A2 (es) 2019-01-18
KR20190026816A (ko) 2019-03-13
GB201611920D0 (en) 2016-08-24
BR112019000240A2 (pt) 2019-04-16
EP3481377A1 (en) 2019-05-15
CL2019000042A1 (es) 2019-04-12
US20200254046A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
AU2016219611A1 (en) Compositions comprising mixtures of semifluorinated alkanes
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
PE20151786A1 (es) Compuestos heterociclicos y sus usos
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
PE20140040A1 (es) Composicion farmaceutica que comprende un inhibidor de la actividad de mek
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
CL2020000747A1 (es) Formulaciones de niraparib.
ECSP15051434A (es) Composición farmacéutica de dosis baja
PH12016500793A1 (en) Turmeric extract containing soft pastilles
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
EA201791009A1 (ru) Композиции, содержащие циклоспорин
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
PE20190321A1 (es) Composiciones farmaceuticas